Whatever happened to nasal sprays

I thought that was an important discovery as regards to treatment, as research suggested that taking nasal sprays of existing medications rather than orally can decrease side effects by upto 80-90 percent.

But, there has been nothing new on the idea of nasal sprays for existing medications ever since.

2 Likes

This is the research I am referring to:

news

New system could deliver schizophrenia medicine directly to brain

A team has created a nasal spray as a drug delivery system to get schizophrenia medication directly to the brain.

A team of neuroscientists and engineers has created a nasal spray to deliver schizophrenia medication directly to the brain instead of having it pass through the body. The study was conducted at McMaster University, Canada.

According to the researchers, the leap in efficiency means patients with schizophrenia, bipolar disorder and other conditions could see their doses of powerful antipsychotic medications cut by as much as three quarters. The researchers explain that a problem for patients using antipsychotic medications is that taking them orally or by injection means the drugs must pass through the body before they reach the brain through the blood. To be sure enough oral or injected medication reaches the brain, a patient must take much more than the brain will ultimately receive, leading to sometimes serious adverse side effects, including weight gain, diabetes, drug-induced movement disorders and organ damage over the long term.

The new method delivers medication in a spray that reaches the brain directly through the nose, enabling the medication to enter the brain directly via the olfactory nerve.

[
New webinar – Monocyte activation test (MAT): Insight into examining regulations and markets prospects
Join this webinar to learn about the current regulations on the monocyte activation test (MAT) and the new type of MAT entering the markets.
Key learning points:

  • Understand the relevance of MAT implementation in EU
  • Learn about the current status of the MAT in the different pharmacopoeia (USP, EP, JP, ChP)
  • Find out how to perform a MAT assay, based on current guidelines
  • Discover what the new MAT assay can offer, such as improving time management and more.
    ](Insight into examining regulations and markets prospects)

“This way we can bypass the blood-brain barrier. By delivering the drug directly to the target, we can avoid side effects below the brain,” said Professor Rm Mishra, one of the authors of the study.

The team had previously created a water-soluble form of the schizophrenia medication PAOPA. The new form they created was easier to manipulate, but they still lacked an effective vehicle for getting it to the brain. A particular issue was that drugs delivered via the nose are typically cleared from the body quickly, requiring frequent re-administration.

The engineering side of the team was able to bind the drug to corn starch nanoparticles that, when sprayed together with a natural polymer derived from crabs, could penetrate deep into the nasal cavity and form a thin gel in the mucus lining, slowly releasing a controlled dose of the drug, which remains effective for treating schizophrenia symptoms over three days. The researchers proved the concept of their new delivery mechanism in rats.

“The corn starch nanoparticles we were using for an industrial application were the perfect vehicle,” said Professor Todd Hoare, one of the authors of the study. “They are naturally derived, they break down over time into simple sugars and we need to do very little chemistry on them to make this technology work, so they are great candidates for biological uses like this.”

The gradual release means patients would only need to take their medication every few days instead of every day or, in some cases, every few hours.

New system could deliver schizophrenia medicine directly to brain

3 Likes

No thanks 1555555

1 Like

there have been some updates according to copilot:

" that was in 2021 any updates

Yes, there have been some updates on the nanoparticle-based drug delivery system (DDS) for schizophrenia since 2021! Researchers have continued to refine and test the system, and recent studies have shown promising results1.

In June 2024, a team from the Japan Advanced Institute of Science and Technology (JAIST) published new findings in the journal JACS Au. They developed a novel DDS where the KS-133 peptide, which targets the VIPR2 receptor, is encapsulated with the brain-targeting peptide KS-4871. This system has been shown to effectively distribute the drug in the brains of mice, improving cognitive functions and reducing side effects associated with traditional antipsychotic drugs.

Additionally, another study from McMaster University in Canada explored a nasal spray delivery system for schizophrenia medication. This method also aims to bypass the blood-brain barrier and deliver medication directly to the brain, potentially reducing side effects and improving treatment efficacy2."

And:

" Recent Developments

In June 2024, researchers from the Japan Advanced Institute of Science and Technology (JAIST) published new findings in the journal JACS Au. They developed a novel nanoparticle-based drug delivery system (DDS) where the KS-133 peptide, which targets the VIPR2 receptor, is encapsulated with the brain-targeting peptide KS-4871. This system has been shown to effectively distribute the drug in the brains of mice, improving cognitive functions and reducing side effects associated with traditional antipsychotic drugs.

Key Findings

  • Effective Drug Distribution: The DDS resulted in the effective distribution of the drug in the brains of mice.
  • Improved Cognitive Functions: Mice treated with the KS-133/KS-487 nanoparticles showed significant improvement in cognitive functions during novel object recognition tests.
  • Inhibition of VIPR2: The treatment was attributed to the inhibition of VIPR2, which is associated with schizophrenia.

Future Directions

  • Further Studies: More research and clinical trials are needed to determine the safety and efficacy of this DDS in humans.
  • Potential for Human Trials: If the results continue to be promising, this could lead to human clinical trials in the near future.

This research is a significant step forward in the treatment of schizophrenia and could potentially revolutionize how we approach mental health disorders. It’s definitely an exciting time in the field of neuroscience!"

3 Likes

also:

" Human trials for new treatments like the nanoparticle-based drug delivery system (DDS) for schizophrenia typically take several years to complete. Here’s a general timeline for clinical trials:

  1. Phase I: Tests the safety, dosage range, and side effects in a small group of healthy volunteers. This phase usually lasts several months.
  2. Phase II: Focuses on the effectiveness of the treatment and further evaluates its safety in a larger group of people with the condition. This phase can take from several months to two years.
  3. Phase III: Involves a larger group of participants to confirm the treatment’s effectiveness, monitor side effects, and compare it to commonly used treatments. This phase can last from one to four years.
  4. Phase IV: Conducted after the treatment has been approved for market use to gather information on its effect in various populations and any side effects associated with long-term use.

Overall, the entire process from initial discovery to full approval can take around 10 to 15 years. However, advancements in technology and accelerated approval processes for certain conditions can sometimes shorten this timeline."

2 Likes

Why on earth not?

A quick snort and you bypass all the below head symptoms drastically.

No more jabs, or pills all affecting the liver and other organs.

Seems like a no brainer to me!

Lol i misread that as “New medicine could deliver schizophrenia directly to the brain”

1 Like

Just the thought of meds shooting straight in my nose to my brain turns me off.
It’s very personal

1 Like

That is trauma!

1 Like

Just breathe this lil doodad right into your nose and voila! You are now the king of thailand :thailand: :grin:

1 Like

I remember reading about how nasal sprays could reduce side effects of medications by up to 80-90%, and honestly, it seemed like such a breakthrough. It made a lot of sense to me since I’ve always felt a bit iffy about taking meds orally because of the potential side effects. But yeah, it’s surprising that we haven’t seen much progress or more research on it since. Maybe the idea just didn’t get the momentum it needed, or there are still too many hurdles in making it work on a larger scale.

1 Like

Precisely. I thought in terms of utility these nasal sprays are better than Cobenfy or any individual medication, as they can be applied to a collection of medications.

1 Like

Meds without side effects… where’s the fun in that :crazy_face: